Among the anti-IL-1 agents, anakinra (recombinant antagonist of the IL-1 receptor), canakinumab (human monoclonal antibody against IL-1β) and rilonacept (a soluble decoy receptor ‘trap’, binding both IL-1α and IL-1β) can be used in the treatment of FMF [13]. The gene discussed is IL1A; the disease is familial Mediterranean fever.